• August 25, 2017

    The Financial Supervision Commission (FSC) registered the shares issued by Tchaikapharma High Quality Medicines Inc. as a result of an increase of the company’s capital with a view to trading on a regulated securities market. This is evident from the regulator’s decisions at the meeting held on the 23rd of August. The equity issue amounts […]

  • July 14, 2017

    The current capital of the pharmaceutical company is BGN 64.3 million. Tchaikapharma High Quality Medicines Inc. announced that following the entry in the Commercial Register the capital of the company was increased by BGN 7.7 million, the announcement came through the BSE-Sofia. The current capital of the pharmaceutical company is BGN 64.3 million, divided into […]

  • June 9, 2017

    The voted dividend for 2016  is 7 700 000. The amount of the capital after the increase is BGN 64 300 000. On June 8, 2017, the Annual General Meeting of Shareholders (GMS) of Tchaikapharma High Quality Medicines Inc. was held with the required quorum. A total of 56,562,089 shares were represented – all with […]

  • April 4, 2017

    On the basis of art.27, par.1. it. 2 of the Ordinance No. 2 of the Financial Supervision Commission (FSC), we notify the following circumstances relating to Tchaikapharma High Quality Medicines Inc., which constitute “internal information” within the meaning of Art. 4 of the Law Against Market Abuse with Financial Instruments and Ordinance No. 2 of […]

  • March 9, 2017

    Bortezomib-Tchaikapharma 3.5 mg powder for solution for injection is Tchaikapharma High Quality Medicines’ newest medicinal product which obtained a Marketing Authorisation by the Bulgarian Drug Agency in the beginning of February 2017. The active substance contained is Bortezomib (as a mannitol boronic ester). The medicinal product is subject to medical prescription. ATC code: L01XX 32

  • February 20, 2017

    Tchaikapharma High Quality Medicines Inc. received another Marketing Authorization by the Bulgarian Drug Agency with which the company updated its list of injectable products. The new oncological drug product is called Pemetrexed-Tchaikapharma 500 mg powder for concentrate for solution for infusion and is used in the treatment of malignant pleural mesothelioma and non-small cell lung […]

  • February 9, 2017

    Bortezomib-Tchaikapharma 3.5 mg powder for solution for injection is Tchaikapharma High Quality Medicines’ newest medicinal product which obtained a Marketing Authorisation by the Bulgarian Drug Agency in the beginning of February 2017. The active substance contained is Bortezomib (as a mannitol boronic ester). The medicinal product is subject to medical prescription. ATC code: L01XX 32

  • February 2, 2017

    Lidocaine-Tchaikapharma 10 mg and 20 mg solution for injection is Tchaikapharma’s newest product which has obtained a Marketing Authorization issued by the Bulgarian Drug Agency. Therapeutic indications: For local anesthesia in surgery, dentistry, urology, cardiology, ophthalmology, otorhinolaryngology and other invasive instrumental investigations. For the treatment of ventricular arrhythmias, including after myocardial infarction and cardiac surgery […]

  • November 15, 2016

    The newest product of Tchaikapharma High Quality Medicines Inc., which BDA gave a marketing authorisation for, is Cilapenem 500 mg/500 mg powder for infusion solution. Each phial contains the following active substances: 530 mg imipenem monohydrate, which is equivalent to 500 mg imipenem anhydrоus, and 532 mg cilastatin sodium, equivalent to 500 mg cilastatin. The drug […]

  • September 2, 2016

    On the Bulgarian pharmaceutical market the latest addition to constantly growing product list of Tchaikapharma High Quality Medicines Inc.  for the treatment of cardiovascular diseases is offered from today. The product Cardesart-Co x 30 tablets, an international non-proprietary name Candesartan/Hydrochlorothiazide, in concentrations of active ingredients 8 mg/12.5 mg and 16 mg/12,5 mg registered under the […]

  • July 19, 2016

    After successfully completing the third for the company Decentralised Procedure (DCP) Tchaikapharma High Quality Medicines Inc. received Marketing Authorisation for the medicinal product Tamayra 5 mg/5 mg hard capsules and Tamayra 10 mg/5 mg hard capsules, for which Bulgaria is the country of reference This is the first international procedure for Marketing Authorisation of medicinal […]

  • July 14, 2016

    Tchaikapharma High Quality Medicines Inc. was granted Marketing Authorisations for the medicinal products Ibodria 6 mg/6 ml concentrate for solution for infusion and Ibodria 3 mg/3 ml solution for injection in pre-filled syringe. The active substance contained is Ibandronic acid (as ibandronate sodium monohydrate). The medicinal product is indicated for the treatment of osteoporosis in […]

  • June 30, 2016

    The Bulgarian Pharmaceutical Union awarded Tchaikapharma High Quality Medicines Inc. for cardiological medicinal product Amariton in the category “Medicinal Product Subject to Medicinal Prescription – made in Bulgaria” for 2016. The Awards ceremony took place at the Tenth anniversary edition of the Bulgarian Pharmaceutical Days, held from the 24th to 26th of June 2016 at […]

  • June 27, 2016

    Tchaikapharma High Quality Medicines Inc. was granted Marketing Authorisations for the medicinal products Atorva 40 mg and 80 mg film-coated tablets. Each tablet contains the active substance atorvastatin as atorvastatin calcium. Atorva is indicated: – as an adjunct to diet to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in adults, adolescents and children […]

  • June 24, 2016

    By decision of the General Meeting, the company’s capital will be increased by BGN 7 million, which will increase in proportion the number of shares that each shareholder has.   On 23rd June 2016, in the presence of the required quorum, was held the Annual General Meeting (AGM) of shareholders of Tchaikapharma High Quality Medicines […]

  • June 22, 2016

    For the past year the company has reported improved results in its financial performance, introducing new products and entering new markets, as well as advancing in the field of its research and development activities   The Public company Tchaikapharma High Quality Medicines Inc. will hold its Annual General Meeting of Shareholders on 23rd of June […]

  • May 13, 2016

    On 10/05/2016, the BDA successfully completed within the specified period the first decentralised procedure (DCP) for marketing authorisation of medicinal products for which Bulgaria is the Reference Member State (RMS). A team of experts from the BDA assessed the documentation, in connection with the Marketing Authorisation of medicinal products Tamayra 5 mg/5 mg hard capsules […]

  • January 22, 2016

    Levor 5 mg/ml infusion solution is a medicinal product of Tchaikapharma High Quality Medicines Inc., for which the Bulgarian Drug Agency issued a marketing authorisation in January 2016. The active substance is levofloxacin as levofloxacin hemihydrate. Levor should be used in adults for treatment of the following infections: Community acquired pneumonia; Complicated skin and soft-tissue […]

  • The Bulgarian Drug Agency issued a marketing authorisation for the medicinal product Cisaxa 2mg/ml injection/ infusion solution. The medicine is a neuromuscular blocking agent with average duration of action for intravenous administration with quantitative composition cisatracurium 2 mg (as cisatracurium besilate 2.68 mg per 1 ml). Cisaxa should be used during surgical and other procedures […]

  • January 4, 2016

    The Bulgarian Drug Agency has issued a marketing authorisation for the medicinal product Remifentanil-Tchaikapharma 1 mg, 5 mg powder for concentrate for solution for injection/infusion, containing the active substance remifentanil and belonging to a group of medicines known as opiates. Remifentanil-Tchaikapharma is used together with other medicines called anaesthetics to: Facilitate falling asleep before surgery; […]

  • Tchaikapharma High Quality Medicines Inc. has obtained a new marketing authorisation for the medicinal product Coolsart – 20 mg/12.5 mg, 20 mg/25 mg, 40 mg/12.5 mg, 40 mg/25 mg film-coated tablets. Coolsart contains two active substances: olmesartan medoxomil and hydrochlorothiazide, which are used to treat high blood pressure (hypertension). Olmesartan medoxomil belongs to the group […]

  • In December 2015 Tchaikapharma High Quality Medicines Inc. was issued a new marketing authorisation by the Bulgarian Drug Agency for the medicinal product Olsart  10 mg, 20 mg, 40 mg film-coated tablets. The medicine contains the active substances olmesartan medoxomil and belongs to a group of medicines called angiotensin-II-receptor antagonists. They lower blood pressure by […]

  • November 4, 2015

    The Bulgarian Drug Agency issued a Marketing Authorisation for a new medicinal product of Tchaikapharma High Quality Medicines Inc. – Aripipa 15 mg tablets – containing the active substance aripiprazole. The medicinal product belongs to a group of drugs called antipsychotics. It is used for treatment of adults and adolescents above 15 years old, suffering […]

  • October 22, 2015

    Tchaikapharma High Quality Medicines Inc. has received new Marketing Authorization for Esomeprazole-Tchaikapharma 40 mg powder for injection / infusion solution. The product contains the active ingredient esomeprazole and belongs to a group of medicines called “proton pump inhibitors”. They work by reducing the amount of acid that the stomach produces. Esomeprazole-Tchaikapharma is used for short-term […]

  • Tchaikapharma High Quality Medicines Inc. has received marketing authorization for the medicinal product Dexketoprofen-Tchaikapharma of 50 mg / 2 ml solution for injection or concentrate for solution for infusion. The product is a pain relieving medicine from the group of the so called Nonsteroidal anti-inflammatory drugs (NSAIDs). It is used for the treatment of acute, […]

  • October 20, 2015

    Tchaikapharma High Quality Medicines Inc. was distinguished among the most profitable and influential companies in Bulgaria for the 2014 business rating “300 Business leaders in Bulgaria”. In this year’s forth edition the business analysts from the ICAP Group rated the most successful companies in the country accordingto the Earnings Before Interest, Taxes, Depreciation, and Amortization […]

  • September 1, 2015

    For the first time the Republic of Bulgaria, as a Member State of the EU, will be the reference country in the decentralized procedure (DCP) for Marketing Authorisation for a medicinal products with applicant Tchaikapharma High Quality Medicines Inc., Bulgaria. The concerned parties in the procedure are Austria, Greece, Portugal, Romania, Slovakia and the Czech […]

  • July 14, 2015

    Bulgarian Drug Agency issued a new Marketing Authorisation to Tchaikapharma High Quality Medicines Inc. for the medicinal product for treatment of diabetes mellitus Aroba 100 mg tablets. Aroba contains the active substance acarbose, and belongs to the group of medicines called alpha-glucosidase inhibitors. It is used as supplement treatment concomitantly with diet in patients with […]

  • May 12, 2015

    June 14, 2015 marks the 10th anniversary from the creation of the Department of Cardiac Surgery at the University Hospital “St. Marina” at the Medical University in Varna “Prof. Dr. Paraskev Stoyanov.” For this occasion, on the 12th  and 13th of  June, a Conference in Cardiology and Cardiac Surgery will be organized in Varna under […]

  • January 20, 2015

    The rating system for assessing of the employers is part of a joint project of the CITUB and the Bulgarian Industrial Association. Tchaikapharma High Quality medicines Inc. is rated second in one of the most competitive and rapidly growing sectors of the economy – production of medicines. The selection of the companies is based on […]

  • November 4, 2014

    Медикаментът е с най-изгодна цена за месечна терапия с инхиботор на протонната помпа – 9.75 лв. За всички останали продукти от същия терапевтичен клас пациентът трябва да доплати за месечно лечение между 11 лв. и 46 лв.

  • October 12, 2010

    The public stance of Tchaikapharma High Quality Medicines regarding the reimbursement and pharmaceutical policy, effective since 2004

    June 10, 2010


    In Bulgaria the first steps to implementation of an effective reimbursement policy were taken in 2004 with the adoption of the Regulation on the Terms, Conditions and Procedures for Contracting Pharmaceuticals, Medical Devices and Diet Foods, Fully or Partially Reimbursed by the National Health Insurance Fund. That was the first time that contract conditions had incorporated the principle of INN reference reimbursement calculated on the basis of similar reference prices in eight EU member states.


    Despite its promising start, the Regulation failed to reduce pharmaceutical spending, improve therapy efficiency, or increase affordability. No price caps were introduced for different therapeutical groups. The national fund refused to control prices for consumers, it only controlled reimbursement. As a consequence, patients’ private costs for pharmaceuticals were increasing annually and Bulgaria became the EU country with the lowest public costs for pharmaceuticals.


    Other important flaws of reimbursement concern the absence of therapeutic goals with focus on chronic diseases and of incentives for the use of generic pharmaceuticals. Only a few of the many shortcomings were corrected when the Positive Drug List Regulation was adopted in 2007. It stipulated limit prices for the generic pharmaceuticals and provided criteria for delisting in case of changes to the efficiency and safety data.


    The feeble Positive Drug List Regulation, however, had a major shortcoming. It is in the fact that the reference for each product is the product itself and not similar products of other manufacturers. So the reference is realized at trademark level and not INN level.


    This reference system effectively caters to the interests of the pharmaceutical giants and may reasonably be called the “Raynov Patent” (Emil Raynov is former Director of the National Health Insurance Fund and former Deputy Minister of Health). The constantly growing public and individual pharmaceutical costs are more than expected, the fiasco is obvious. In 2008 the spending of the National Health Insurance Fund amounted to BGN 295 million, while in 2009 it was as much as BGN 400 million. What is more, the country also had the highest personal pharmaceutical costs – an average of 60%.


    The following objectives have to be high-priority in NHIF’s pharmaceutical and reimbursement policy:
    – Improved access to pharmaceuticals, especially for the socially significant chronic diseases. This would improve long-term control and postpone or even prevent a large number of hospitalizations. Therefore, these diseases should be treated with completely or at least 90 % reimbursable therapies.
    – Encouraging the use of generics. This could reduce pharmaceutical spending by more than 30%.


    We should not underestimate the powerful influence exerted on prescribing physicians by the pharmaceutical manufacturers’ medical representatives in favor certain medicines. This magnifies the negative effect both on the quality and on the access to therapies. Public and private costs increase too.


    The National Health Insurance Fund is unable to curb this influence, so patient control over the prices of pharmaceutical therapies should be encouraged. This could be achieved if reimbursement values are defined for the full cycle necessary to treat a diagnosis or a combination of such and not for the pharmaceutical. Practically, this would mean determining of reference prices for therapies at the disease level (ICD) and not at the therapy level (ATC). For each disease at ICD level there shall be at least one option for a 100% reimbursable therapy.


    The therapy-based reimbursement system has a number of advantages:
    – Reduced pharmaceutical prices lead to reduced personal, and not public, costs. It is the exact opposite of the reference-price-based reimbursement and would have a significant social effect.
    – Pharmaceutical costs could be easily forecasted as they would depend only on the number of diagnosed patients and not on the choices of the prescribing physicians
    – Much more simplified control over the prescription, dispensing and reimbursement of pharmaceuticals and much lower related costs


    The control over the prescription and use of pharmaceuticals may be strengthened even further if patients exercise financial control over doctors and pharmacists. This would be possible if there is to be a transition from a reimbursement system to a refunding system.